CNDO Key Stats
- CORONADO BIOSCIENCES INC Financials May 17
- Wall Street Transcript Interview with Finny Kuruvilla, Portfolio Manager of the ... May 16
- Nasdaq stocks posting largest percentage decreases May 13
- CORONADO BIOSCIENCES INC Files SEC form 10-Q, Quarterly Report May 9
- Coronado Biosciences' CEO Discusses Q1 2013 Results - Earnings Call Transcript Seeking Alpha May 8
- Coronado Bio (CNDO) Posts Q1 Loss of 35c/Share Street Insider May 8
- Coronado Biosciences Reports Financial Results for the First Quarter Ended March... May 8
- Q1 2013 Coronado Biosciences Earnings Release - Before Market Open May 8
- CORONADO BIOSCIENCES INC Files SEC form 8-K, Results of Operations and Financial... May 8
- Coronado Biosciences Appoints Thomas F. Schaible, Ph.D. as Project Leader, Infla... May 7
CNDO Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Coronado Biosciences is up 54.21% over the last year vs S&P 500 Total Return up 31.68%, Clovis Oncology up 99.62%, and ACADIA Pharmaceuticals up 834.5%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for CNDO
Pro Report PDF for CNDO
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download CNDO Pro Report PDF
Pro Strategies Featuring CNDO
Did Coronado Biosciences make it into our Pro Portfolio Strategies?